Pharmafile Logo

News and Press Releases

Outlook Therapeutics Announces NICE Recommendation of LYTENAV (bevacizumab gamma) for the Treatment of Wet AMD

First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD...

Category:
Posted: December 6, 2024

Outlook Therapeutics
info@outlooktherapeutics.com
Outlook Therapeutics, Inc. 111 S. Wood Ave Unit,100 Iselin, NJ 08830

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan disease OKYO is the first company to have an IND application granted by...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 16, 2024

OKYO Pharma
info@okyopharma.com
OKYO Pharma Floor 4, 14/15 Conduit St London W1S 2XJ

Professor V. A. Bumelis opens the Lithuanian Museum of Biotechnology

20 September 2024 – Savaitiskes, Lithuania –The 40th anniversary of the Lithuanian biopharmaceutical industry and science was marked on Monday with the opening of the Lithuanian Biotechnology Museum in the...

Category: Biotechnology, Other
Posted: September 20, 2024

Northway Biotech

Signant Health Appoints 20-Year Life Sciences Veteran Paul Richmond to executive leadership team as chief commercial officer

15 July 2024 – Pennsylvania, US – Signant Health, the leader in evidence generation for modern clinical trials, announced today the appointment of Paul Richmond as chief commercial officer. A...

Category: Clinical Trials, Other, Pharmaceutical
Posted: July 16, 2024

Signant Health
media@signanthealth.com
4000 Chemical Road Suite 300 Plymouth Meeting, PA 19462

Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz

Just – Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term...

Category: BioManufacturing, Biotechnology
Posted: July 10, 2024

Just – Evotec Biologics
info@evotec.com
Just – Evotec Biologics, Inc. 401 Terry Avenue North Seattle, WA 98109, US

Formycon receives FDA approval for FYB203/ AHZANTIVE) (aflibercept-mrbb), a biosimilar to Eylea

1 July 2024, Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) and its licencing partnerKlinge Biopharma GmbH ("Klinge") jointly announce that the U.S. Food and Drug Administration ("FDA")approved FYB203/AHZANTIVE (aflibercept-mrbb),...

Category: Pharmaceutical
Posted: July 1, 2024

Formycon
inof@formycon.com
Formycon AG, Fraunhoferstraße 15, 82152 Martinsried/Planegg, Germany

Formycon reports on the results of the annual general meeting

Management provides detailed report on financial year 2023 and current company performance. Shareholders approve all agenda items and formally approve the acts of the members of the management board and...

Category: BioManufacturing
Posted: June 13, 2024

Formycon
inof@formycon.com
Formycon AG, Fraunhoferstraße 15, 82152 Martinsried/Planegg, Germany

Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe

30 November 2023 -- Bengaluru, India -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, today announced that the integration of the Viatris’ biosimilars business in 31 European countries has been successfully...

Category: Pharmaceutical
Posted: November 30, 2023

Biocon Biologics
contact@bioconbiologics.com
Biocon House, Semicon Park Electronics City, Phase – II, Hosur Road Bengaluru 560100, Karnataka, India